Combining EPI-7386 With Enzalutamide and Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer

NCT06312670 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

13

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
Prostate Cancer
Prostate Adenocarcinoma

Interventions

DRUG: EPI-7386
DRUG: Enzalutamide
DRUG: Androgen Deprivation Therapy (ADT)

Sponsor

Pedro Barata, MD, MSc

Collaborators

[object Object]